MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.40
+0.41
+0.87%
Opening 15:38 12/04 EST
OPEN
47.05
PREV CLOSE
46.99
HIGH
47.70
LOW
46.53
VOLUME
83.08K
TURNOVER
--
52 WEEK HIGH
62.41
52 WEEK LOW
33.80
MARKET CAP
617.63M
P/E (TTM)
133.75
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eagle Pharmaceuticals Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing
Business Wire · 11/23 11:50
Eagle Pharmaceuticals' Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the Company's pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below:
BusinessWire · 11/23 08:50
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders
--Highlights That Chairman Scott Tarriff has Fostered an Anti-Shareholder Culture Defined by Dilutive Actions, Poor Investor Engagement, and a Misaligned Management Team
BusinessWire · 11/05 11:05
Vasopressin for Vasoplegic Shock Market to Exhibit Stellar 14.8% CAGR and Reach USD 2,657.9 Million by 2027; Owing to Increasing Prevalence of Cardiovascular Surgeries, reports Fortune Business Insights(TM)
The global vasopressin for vasoplegic shock market size is expected to gain momentum by reaching USD 2,657.9 million by 2027, while exhibiting a stellar CAGR of 14.8% between 2020 and 2027. This is attributable to the increasing prevalence of cardiovascular surgeries that propels the demand for vasopressin for vasoplegic shock across the globe. The report further mentions that the market stood at USD 890.9 million in 2019. North America stood at USD 561.3 million in 2019 and is expected to hold the highest position in the global market in the forthcoming years.
GlobeNewswire · 11/04 07:28
Eagle Pharmaceuticals EPS beats by $0.88, beats on revenue
Eagle Pharmaceuticals (EGRX): Q3 Non-GAAP EPS of $1.17 beats by $0.88; GAAP EPS of $0.51 beats by $0.49.Revenue of $49.93M (+21.3% Y/Y) beats by $2.95M.Press Release
Seekingalpha · 11/02 11:57
Eagle Pharmaceuticals Reports Third Quarter 2020 Results
-- Granted Priority Review by U.S. Food and Drug Administration ("FDA") for vasopressin; trial date set for January 11, 2021 --
BusinessWire · 11/02 08:47
Eagle Pharmaceuticals to Discuss Third Quarter 2020 Financial Results on November 2, 2020
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Monday, November 2, 2020, before the market opens.
BusinessWire · 10/26 17:30
Summers Value Partners Q3 2020 Investor Letter
Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate.The Summers Value Fund LP declined by 1.2% net during the first nine months of 2020, outpacing the Russell 2000 Index return of -9.6% and the Russell Microcap Index return of -9.1%.Our shorting activities continue to be limited as we wait for better opportunities. The Fund has generated a small loss on the short side year-to-date.We currently have more ideas than we do capital. We added two new positions in the third quarter, and our idea funnel remains full.
Seekingalpha · 10/15 19:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EGRX. Analyze the recent business situations of Eagle Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EGRX stock price target is 50.00 with a high estimate of 57.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 266
Institutional Holdings: 16.16M
% Owned: 124.03%
Shares Outstanding: 13.03M
TypeInstitutionsShares
Increased
66
1.53M
New
44
33.64K
Decreased
51
1.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.01%
Pharmaceuticals & Medical Research
+1.43%
Key Executives
Chairman/Independent Director
Michael Graves
President/Chief Operating Officer
David Pernock
Chief Executive Officer/Director
Scott Tarriff
Chief Financial Officer/Chief Accounting Officer
Brian Cahill
Independent Director
Richard Edlin
Independent Director
Robert Glenning
Independent Director
Steven Ratoff
Independent Director
Jennifer Simpson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EGRX
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.